Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.46 |
| ▸ | ARG1 | P05089 | 1/20 | 0.40 |
| ▸ | ARG2 | P78540 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 3/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12728385 | 1.00 | ALDH1A1 (0.46) | ALDH1A1ALOX15TRPA1CYP3A4HPGD | |
| SCHEMBL1158206 | 1.00 | ALDH1A1 (0.46) | ALDH1A1ALOX15TRPA1CYP3A4HPGD | |
| SCHEMBL20420850 | 0.93 | GRIK1 (0.41) | ALDH1A1ALOX15TRPA1CYP3A4HPGD | |
| Cystine SCHEMBL8332360 | 0.84 | PTGS1 (0.50) | ALDH1A1ALOX15GRIK1GRIK2ARG1 | |
| Cystine SCHEMBL10224 | 0.84 | PTGS1 (0.50) | ALDH1A1ALOX15GRIK1GRIK2ARG1 | |
| Cystine SCHEMBL8332356 | 0.84 | PTGS1 (0.50) | ALDH1A1ALOX15GRIK1GRIK2ARG1 | |
| Cystine SCHEMBL8332353 | 0.84 | PTGS1 (0.50) | ALDH1A1ALOX15GRIK1GRIK2ARG1 | |
| Cystine SCHEMBL10225 | 0.84 | PTGS1 (0.50) | ALDH1A1ALOX15GRIK1GRIK2ARG1 | |
| Cystine SCHEMBL21114356 | 0.84 | PTGS1 (0.50) | ALDH1A1ALOX15GRIK1GRIK2ARG1 | |
| Cystine SCHEMBL5018669 | 0.84 | PTGS1 (0.50) | ALDH1A1ALOX15GRIK1GRIK2ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3970793-A1 | AGENT FOR PREVENTING, AMELIORATING, OR TREATING PERIODONTAL DISEASE | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2022-03-23 | — | — | EP | disclosed |
| WO-2020230813-A1 | AGENT FOR PREVENTING, AMELIORATING, OR TREATING PERIODONTAL DISEASE | 湧永製薬株式会社 | 2020-11-19 | — | — | WO | disclosed |
| WO-2017050314-A1 | FOOD ADDITIVE COMPRISING BIO-ACTIVE COMPONENTS OF GARLIC | CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL (DE) | 2017-03-30 | — | — | WO | disclosed |
| US-9226885-B2 | Personal care and medicinal products incorporating bound organosulfur groups | ALLIUM VITALIS INCORPORATED (US) | 2016-01-05 | — | — | US | disclosed |
| US-8623919-B2 | Method of synthesizing S-allyl-cysteine analogues and their therapeutic application in treating myocardial infarction | FUDAN UNIVERSITY (CN) | 2014-01-07 | — | — | US | disclosed |
| US-8623919-B2 | Method of synthesizing S-allyl-cysteine analogues and their therapeutic application in treating myocardial infarction | FUDAN UNIVERSITY (CN) | 2014-01-07 | — | — | US | disclosed |
| US-8236533-B2 | Process for the production of γ-glutamylcysteine | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2012-08-07 | — | — | US | disclosed |
| US-8217084-B2 | Medicinal products incorporating bound organosulfur groups | ALLIUM VITALIS INCORPORATED (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120149940-A1 | Integrin Modulators and Methods for Their Use | BILLINGS PHARMACEUTICALS, INC. | 2012-06-14 | — | — | US | disclosed |
| EP-2186512-A1 | USE OF ALLYLCYSTEINE OR ITS ANALOGS AND PHARMACEUTICAL COMPOSITION THREROF | Fudan University (CN) | 2010-05-19 | — | — | EP | disclosed |
| US-7678833-B2 | Method to increase the bioavailability of cysteine | ALLIUM VITALIS INCORPORATED (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090136993-A1 | Process for the Production of Gamma-Glutamylcysteine | NEWSOUTH INNOVATIONS PTY LIMITED | 2009-05-28 | — | — | US | disclosed |
| US-20090036534-A1 | Method Of Synthesizing S-Allyl-Cysteine Analogues And Their Therapeutic Application In Treating Myocardial Infarction | FUDAN UNIVERSITY (CN) | 2009-02-05 | — | — | US | disclosed |
| US-20090036534-A1 | Method Of Synthesizing S-Allyl-Cysteine Analogues And Their Therapeutic Application In Treating Myocardial Infarction | FUDAN UNIVERSITY (CN) | 2009-02-05 | — | — | US | disclosed |
| US-20080234388-A1 | Integrin Modulators and Methods for their Use | BILLINGS PHARMACEUTICALS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234388-A1 | Integrin Modulators and Methods for their Use | BILLINGS PHARMACEUTICALS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20070275876-A1 | Method to increase the bioavailability of cysteine | ALLIUM VITALIS INCORPORATED | 2007-11-29 | — | — | US | disclosed |
| EP-1028117-B1 | Novel protein: prenyl transferase inhibitors | TNO (NL) | 2002-06-12 | — | — | EP | disclosed |
| US-6376468-B1 | TETRAPEPTIDE CONTAINS CONFORMATIONALLY RESTRICTED DIPEPTIDE ISOSTER MOIETIES WHICH HAS HETEROCYCLE IN THE CENTRAL PART WHICH REDUCES THE FLEXIBILITY; INHIBITING ONCOGENESIS AND OTHER UNWANTED CELL PROLIFERATION, SUPRESSING ABERRANT HIGH | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2002-04-23 | — | — | US | disclosed |
| EP-1028117-A2 | Novel protein: prenyl transferase inhibitors | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2000-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234388-A1 | Integrin Modulators and Methods for their Use | ITGA5, ITGB1, ITGB5 | ALDH1A1 527/4885ALOX15 383/4885TRPA1 809/4885 |
| US-20120149940-A1 | Integrin Modulators and Methods for Their Use | ITGA5, ITGB1, ITGB5 | ALDH1A1 527/4885ALOX15 383/4885TRPA1 809/4885 |
| US-20070275876-A1 | Method to increase the bioavailability of cysteine | CTH, CBS, SLC7A1 | ALDH1A1 1672/4885ALOX15 894/4885TRPA1 2337/4885 |
| US-20090036534-A1 | Method Of Synthesizing S-Allyl-Cysteine Analogues And Their Therapeutic Application In Treating Myocardial Infarction | SRM, SMS, SCLY | ALDH1A1 1122/4885ALOX15 2011/4885TRPA1 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.